Author(s):
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
Approximately 13,000 individuals are diagnosed with cervical cancer and more than 4,000 die each year in the United States, according to the Centers for Disease Control and Prevention. Recent research published in JAMA additionally notes that nearly one in three women in the US may never have been screened for cervical cancer, and millions more are behind on their annual exams.
When caught early, this cancer type is highly treatable. Abnormal cells found in the cervix can even be removed years before they develop into cancer, underscoring the importance of early detection. Although the rate of diagnoses is down from a generation ago in the US, incidence and mortality rates have both plateaued over the past decade, according to the National Cancer Institute (NCI). However, the FDA approval of the first at-home cervical cancer screening test in 2025 may further improve these outcomes by breaking down barriers to access and enhancing patient convenience while maintaining the same level of accuracy as an in-clinic test.
With this method, patients meet virtually with a board-certified obstetrician-gynecologist, receive and use the testing kit, ship it back, and see results and any applicable next steps delivered through a patient portal, all from the comfort of home. This technology uses primary human papillomavirus (HPV) testing, which is preferred over the traditional Pap smear due to its sensitivity to precancerous cellular changes and more accurate long-term risk prediction. According to the World Health Organization, almost all cervical cancer cases have been linked to HPV infection.
Despite FDA approval, the United States Preventive Services Task Force, the nation’s independent body for healthcare recommendations, has yet to adopt the at-home option within its guidelines. This absence, combined with low awareness of an alternative option, is why most patients still default to in-clinic testing. Importantly, providers should also note that Medicare and Medicaid are not currently accepted for the at-home test, including self-pay for patients under those plans.
Among potential patients who are aware of at-home testing, disparities have been observed across racial, geographic, and socioeconomic lines. A study from researchers in Texas examined NCI’s Health Information National Trends Survey data, a report of Americans’ health preferences, knowledge, and awareness. The most recent version was administered to more than 7,000 individuals in 2024 and was the first to mention at-home self-screening for cervical cancer. Participants were asked the following questions:
Only 20% of women surveyed preferred at-home self-sampling over screening administered by their provider, while nearly the same number (19%) were unsure which they would prefer. When drilling into respondent data further, researchers found that White individuals living in rural areas were likelier than urban residents and other racial groups to prefer self-screening.
Because it is shipped directly to patients, the at-home test can be appealing to patients experiencing social drivers of health, such as a lack of transportation or long distance from a provider. Additionally, at-home screening reduces the need to take time off work or secure childcare for a doctor’s appointment, which are other commonly cited reasons for delayed screening.
According to the study, people of color were less likely to prefer the self-screening option and more likely to be unsure of their preference. These same demographic groups are also less likely than their White counterparts to be up to date on cervical cancer screening recommendations, regardless of method, according to the NCI.
“The majority of cervical cancers are among those who are never screened,” said Sanjay Shete, PhD, of the Department of Biostatistics at The University of Texas MD Anderson Cancer Center and one of the study’s authors, highlighting the need for more effective screening strategies to reach demographic groups that are currently left out.
For patients who experience psychological social drivers of health, such as past medical trauma or a general distrust of the medical system, at-home testing can also provide a higher level of comfort and control by meeting providers in an environment that feels safe. The test itself is a small self-swab that does not require a speculum, which can also be a significant benefit for patients with genito-pelvic pain/penetration disorders, such as vaginismus.
Education is a powerful tool for informing patients about their options and breaking down misconceptions that may prevent care, such as the idea that at-home testing is less accurate. Looking forward, Dr. Shete and his team will deploy a separate survey across Texas to gather more feedback on barriers to at-home screening, in hopes of boosting screening rates and ultimately improving health outcomes for all.
Visit ACCC's Gynecologic Cancer education and resource page to learn more about initiatives aimed at reducing the burden of cancers originating in the endometrium, ovaries, or cervix.
Decentralized clinical trial approaches, including remote consent, telehealth, local laboratory and imaging services, and more, can help reduce some of the many barriers that prevent eligible patients from participating in trials. But as the participants in ACCC’s Advancing Decentralized Clinical Trials in the Community Setting Roundtable Series emphasized, implementing DCT elements is not simply a matter of adopting new technology. Doing so successfully requires thoughtful workflows and oversight structures that consider equity, scalability, and sustainability.
